Expanding the Benefits of PARP Inhibitors to More Patients With Breast Cancer and Earlier Settings

preview_player
Показать описание
  1. PeerView CME
  2. Dr. Henry Kuerer
  3. Dr. William Gradishar
  4. Dr. Heather McArthur
  5. CME
  6. meded
Рекомендации по теме
Expanding the Benefits 1:13:00

Expanding the Benefits of PARP Inhibitors to More Patients With Breast Cancer and Earlier Settings

Learn all about 0:58:46

Learn all about PARP inhibitors with Dr Jon Krell, Consultant Medical Oncologist

BRCA & PARP 0:11:49

BRCA & PARP Inhibitors: Targeted Chemotherapy | #MarkScholzMD #AlexScholz @PCRI

Maximizing the potential 0:35:35

Maximizing the potential of PARP inhibitors as first-line maintenance therapy in ovarian cancer

Clinical Advances in 0:40:57

Clinical Advances in Ovarian Cancer: Exploring the Expanding Role of PARP Inhibitors in the Treat...

Ovarian Cancer: How 0:06:40

Ovarian Cancer: How PARP Inhibitors Work

Dr Gong on 0:01:27

Dr Gong on the Benefits and Limitations of PARP Inhibitor–Based Regimens in mCRPC

The evolving role 0:01:53

The evolving role of PARP inhibitors in mCRPC

New FDA Approved 0:14:39

New FDA Approved PARP Inhibitor: Talzenna (Talazoparib) & Xtandi | #markscholzmd #AlexScholz #pc...

New Treatment on 0:03:26

New Treatment on the Horizon | PARP inhibitor - olaparib

PARP Inhibitors: 2023 0:18:28

PARP Inhibitors: 2023 Updates

Personalizing Advanced Ovarian 0:57:11

Personalizing Advanced Ovarian Cancer Treatment With PARP Inhibitors and Novel Approaches

Updates in Ovarian 0:26:02

Updates in Ovarian Cancer: Frontline Maintenance

PARP Inhibitors for 0:34:17

PARP Inhibitors for the Treatment of Ovarian Cancer - Gottfried Konecny, MD | UCLAMDChat

Ongoing Clinical Trials 0:18:37

Ongoing Clinical Trials with PARP Inhibitors in Ovarian Cancer

The PARP Revolution: 0:50:29

The PARP Revolution: How PARP inhibitors are changing the landscape of ovarian cancer treatment

ACTG Dinner Symposium 0:29:07

ACTG Dinner Symposium Highlights | Beyond BRCA testing – does HRD matter? | Prof Michael Friedlander...

Target Practice: Understanding 1:27:32

Target Practice: Understanding How PARP Inhibitors Take Aim at DDR Mutations Across Solid Tumors

Role of PARP 0:16:22

Role of PARP Inhibitors in Prostate Cancer

Identifying Mutations and 0:21:53

Identifying Mutations and Optimizing Use of PARP Inhibitors

What’s New with 0:58:44

What’s New with PARP Inhibitors and Ovarian Cancer?

PARP Inhibitors Advance 0:00:54

PARP Inhibitors Advance Beyond Treatment of BRCA1/2-Mutant Gynecologic Cancers

PARP inhibitors: activity 0:03:56

PARP inhibitors: activity in BRCA1 versus BRCA2 altered mCRPC

The Role of 0:51:57

The Role of PARP in Early Stage Breast Cancer